Molbio Diagnostics IPO receives a Selective Apply recommendation from Chanakya.
The company operates in the specialised and expanding molecular-diagnostics segment.
Its healthcare-technology business offers promising long-term growth potential.
The IPO price band is Rs. 768–Rs. 807, with a lot size of 18 shares.
Minimum retail investment at the upper price is Rs. 14,526.
The Rs. 939.85 crore issue includes only Rs. 200.16 crore as fresh capital.
The larger Rs. 739.70 crore OFS will not provide funds to the company.
A GMP of around Rs. 130 indicates an estimated listing gain of nearly 16%.
However, GMP is unofficial, volatile and cannot guarantee the listing performance.
Listing-gain investors should monitor QIB demand and total subscription before applying.
Strong institutional bidding and stable GMP would improve the issue’s prospects.
Long-term investors should assess valuation, earnings growth and competitive risks carefully.
Study all the aspects of this IPO
Related Market Insights
- 📊 Chanakya Market Dashboard
- 📈 Gift Nifty Live Analysis
- 📉 Nifty Levels Today
- 🏦 Bank Nifty Levels Today
- 🛢 Crude Oil Outlook
- 🥇 Gold Price Outlook
- 💵 USDINR Strategy
- 🏭 Reliance Levels Today
- 🏦 SBI Levels Today
- 🚀 PG’s Breakout Stocks Today
- ⚡ Nilesh Kotak’s Breakout Call
- ☕ Coffee Can Stock of the Week
Final Guidance: Selective Apply for listing gains, subject to firm GMP and strong QIB subscription.